Otsuka Holdings (TSE:4578) Lifts Guidance Following Earnings Upgrade and Fair Value Stays In Focus

Otsuka Holdings (TSE:4578) has just lifted its earnings guidance for the first half of 2026, citing stronger business performance, delayed generic competition for key drugs, currency tailwinds, and lower research and development spending.

See our latest analysis for Otsuka Holdings.

Even with the recent guidance upgrade and upcoming H1 2026 earnings call on 31 July, Otsuka Holdings' share price has eased slightly over the past week. However, the 1 month share price return of 4.08% and year to date share price return of 22.67% come alongside a 1 year total shareholder return of 50.94%. This sits within a much stronger three and five year total shareholder return record and indicates that longer term momentum has been firmly positive.

If this kind of rerating story has your attention, it can also be a useful moment to widen your watchlist with 6 healthcare AI stocks

After Otsuka Holdings' guidance lift and strong recent share price run, the tension is clear. Does it make more sense to pay up now for that new outlook, or wait for a cheaper entry if enthusiasm cools?

Most Popular Narrative: 14.8% Undervalued

Using the most followed narrative, Otsuka Holdings' fair value of ¥13,025 sits above the last close of ¥11,100, which frames the current debate around how much optimism is already reflected in the price.

Otsuka's pharmaceutical segment is benefiting from strong growth in CNS and specialty drug franchises like REXULTI and JYNARQUE, supported by rising global healthcare demand for mental health and chronic disorder therapies, setting the foundation for sustained revenue growth and high net margins as the patient pool expands.

Read the complete narrative.

Want to see what sits behind that earnings story? The narrative leans on measured revenue growth, stable margins, and a richer future earnings multiple. Curious which specific assumptions bridge today’s price to that fair value target.

Result: Fair Value of ¥13,025 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to factor in real risks for Otsuka Holdings, including patent expiries on key drugs and the possibility that higher R&D or deal spending fails to pay off.

Find out about the key risks to this Otsuka Holdings narrative.

Next Steps

With sentiment around Otsuka Holdings looking constructive, it can help to move quickly, review the underlying data, and weigh it against your own expectations. To see what optimistic investors are focusing on, take a closer look at the 4 key rewards

Looking for more investment ideas beyond Otsuka Holdings?

Do not stop with just one stock. Use the Simply Wall St Screener to quickly spot fresh opportunities that match the kind of portfolio you want to build.

• Target dependable income by scanning companies that appear in the 42 dividend fortresses and see which yields stand out for you.
• Spot potential bargains early by reviewing the 18 high quality undervalued stocks and compare how their fundamentals line up with your return goals.
• Reduce unwanted surprises by focusing on the 60 resilient stocks with low risk scores so you can keep your shortlist tilted toward more resilient businesses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com